Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen)

Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen)

Radioligand therapy is a type of internal radiotherapy combining a short-range radioisotope labeled to a carrier with a high affinity for a specific receptor expressed on tumor cells. Targeted alpha therapy (TAT) combines a high-linear energy transfer (LET) emitter (225Ac) with a prostate-specific m...

Full description

Bibliographic Details
Main Authors: Maria Luisa Belli, Anna Sarnelli, Emilio Mezzenga, Francesco Cesarini, Paola Caroli, Valentina Di Iorio, Lidia Strigari, Marta Cremonesi, Antonino Romeo, Silvia Nicolini, Federica Matteucci, Stefano Severi, Giovanni Paganelli
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Oncology
Subjects:
target alpha therapy (TAT)
prostate-specific membrane antigen (PSMA)
xerostomia
theragnostic
protectors
dosimetry
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.531660/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.531660/full

Similar Items